Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

Phase 4
Completed
Conditions
Interventions
First Posted Date
2014-02-04
Last Posted Date
2022-09-14
Lead Sponsor
Boca Raton Regional Hospital
Target Recruit Count
250
Registration Number
NCT02053909
Locations
🇺🇸

Boca Raton Regional Hospital, Boca Raton, Florida, United States

🇨🇦

University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy

First Posted Date
2014-01-30
Last Posted Date
2018-02-22
Lead Sponsor
Sheba Medical Center
Target Recruit Count
29
Registration Number
NCT02049762
Locations
🇮🇱

Sheba Medical Center, Tel-Hashomer, Israel

Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis

Early Phase 1
Terminated
Conditions
Interventions
First Posted Date
2014-01-28
Last Posted Date
2021-05-17
Lead Sponsor
Yale University
Target Recruit Count
1
Registration Number
NCT02047539
Locations
🇺🇸

PRIME Research Clinic, New Haven, Connecticut, United States

Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD

First Posted Date
2014-01-27
Last Posted Date
2024-05-21
Lead Sponsor
Stefan Engelter
Target Recruit Count
194
Registration Number
NCT02046460
Locations
🇩🇰

University Hospital, Stroke Center Bispebjerg Hospital Copenhagen, Denmark, Copenhagen, Denmark

🇨🇭

University Hospital, Stroke Center Basel, Switzerland, Basel, Switzerland

🇩🇪

University Hospital, Stroke Center Charite Berlin, Germany, Berlin, Germany

and more 7 locations

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)

Phase 4
Completed
Conditions
Interventions
First Posted Date
2014-01-23
Last Posted Date
2021-04-14
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
5530
Registration Number
NCT02044250
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Safety Study of APD-791 With Aspirin and/or Clopidogrel

First Posted Date
2014-01-13
Last Posted Date
2019-02-15
Lead Sponsor
IlDong Pharmaceutical Co Ltd
Target Recruit Count
16
Registration Number
NCT02034292

Effect of Herbal Products on Platelet Function and Clotting

First Posted Date
2013-12-11
Last Posted Date
2015-11-20
Lead Sponsor
Singapore General Hospital
Target Recruit Count
75
Registration Number
NCT02008981
Locations
🇸🇬

Singapore General Hospital, Singapore, Singapore

Cilostazol Stroke Prevention Study for Antiplatelet Combination

First Posted Date
2013-11-26
Last Posted Date
2019-03-28
Lead Sponsor
Japan Cardiovascular Research Foundation
Target Recruit Count
1884
Registration Number
NCT01995370
Locations
🇯🇵

Japan Cardiovascular Research Foundation, Osaka, Japan

The Effects of DHA on Periodontitis

First Posted Date
2013-11-06
Last Posted Date
2017-12-13
Lead Sponsor
Beth Israel Deaconess Medical Center
Target Recruit Count
55
Registration Number
NCT01976806
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

ASPREE Cancer Endpoints Study

Phase 4
Conditions
Interventions
First Posted Date
2013-10-24
Last Posted Date
2021-04-05
Lead Sponsor
Hennepin Healthcare Research Institute
Target Recruit Count
14500
Registration Number
NCT01968798
Locations
🇺🇸

Emory/ Atlanta VAMC, Atlanta, Georgia, United States

🇺🇸

The Brody School of Medicine at ECU, Greenville, North Carolina, United States

🇺🇸

New Jersey Medical College, Newark, New Jersey, United States

and more 37 locations
© Copyright 2024. All Rights Reserved by MedPath